SIP
CRMD icon

Stoneridge Investment Partners’s CorMedix CRMD Stock Holding History

Stoneridge Investment Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99K Buy
+13,129
New +$104K 0.06% 139

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stoneridge Investment Partners's CRMD Position: Q2 2026 in Review

Stoneridge Investment Partners opened a new position in CorMedix (CRMD) in Q2 2026: 13,129 shares worth $99K. The stake represents 0.06% of the portfolio and ranks #139 among its holdings.

194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Stoneridge Investment Partners held 13,129 shares of CorMedix worth $99K as of Q2 2026.
  • CorMedix was a new Stoneridge Investment Partners position in Q2 2026.
  • CorMedix made up 0.06% of Stoneridge Investment Partners's portfolio in Q2 2026, its #139 holding.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.